Study finds that the Pfizer-BioNTech COVID-19 vaccine is effective against the B.1.617.2 Delta variant
A new study published in BMC Infectious Diseases has found that the Pfizer-BioNTech COVID-19 vaccine is effective against the highly transmissible B.1.617.2 Delta variant. The study analyzed blood samples from individuals who received two doses of the Pfizer-BioNTech vaccine and found that the vaccine produced neutralizing antibodies against the Delta variant at levels comparable to the original strain of the virus. The Delta variant, which was first identified in India, has become a major concern around the world due to its increased transmissibility and potential to cause more severe disease. This study provides further evidence that the Pfizer-BioNTech vaccine is effective against this variant, which has now spread to over 60 countries. However, the study also highlights the need for continued monitoring of the effectiveness of COVID-19 vaccines against emerging variants.